Chardan Capital reiterated their buy rating on shares of Synlogic (NASDAQ:SYBX) in a research report sent to investors on Tuesday morning. They currently have a $20.00 target price on the biotechnology company’s stock.
“We continue to be encouraged by the preclinical studies (1, 2) and the healthy volunteer data which demonstrated measurable effects on biomarkers of engineered bacterial metabolism even in the context of functional host metabolic processes. We also see the work done to standardize the measurement of key analytes across trial sites as valuable groundwork for robust readouts. With respect to anticipated therapeutic thresholds targeted for these products, both are aiming for fairly moderate impacts on toxic metabolite levels, specifically a 15%-20% lowering of blood ammonia in the hepatic encephalopathy patients after SYNB1020 treatment and a doubling (from ~6 g to ~12 g) of protein tolerated in PKU patients treated with SYNB1618. Of note, the trial of SYNB1618 is not powered to detect significant differences Phe lowering, but will inform future endpoints and target profiles.”,” the firm’s analyst wrote.
Several other research firms have also recently issued reports on SYBX. HC Wainwright set a $20.00 target price on shares of Synlogic and gave the company a buy rating in a research note on Monday, December 10th. Zacks Investment Research cut shares of Synlogic from a buy rating to a hold rating in a research note on Saturday, January 5th. ValuEngine cut shares of Synlogic from a buy rating to a hold rating in a research note on Wednesday, January 2nd. BTIG Research initiated coverage on shares of Synlogic in a research note on Tuesday, February 12th. They issued a buy rating and a $22.00 target price for the company. Finally, Oppenheimer set a $18.00 target price on shares of Synlogic and gave the company a buy rating in a research note on Monday, November 12th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $18.59.
Synlogic (NASDAQ:SYBX) last posted its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.09. Synlogic had a negative net margin of 1,922.02% and a negative return on equity of 35.58%. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.24 million. Research analysts anticipate that Synlogic will post -2.46 earnings per share for the current year.
In other Synlogic news, insider Paul Francis Miller sold 9,000 shares of the company’s stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $9.75, for a total transaction of $87,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 23.30% of the company’s stock.
A number of large investors have recently bought and sold shares of SYBX. Legal & General Group Plc acquired a new position in Synlogic during the third quarter worth $33,000. American International Group Inc. acquired a new position in Synlogic during the third quarter worth $145,000. Rhumbline Advisers raised its position in Synlogic by 45.7% during the fourth quarter. Rhumbline Advisers now owns 21,753 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 6,820 shares during the period. TIAA CREF Investment Management LLC acquired a new position in Synlogic during the third quarter worth $251,000. Finally, Fosun International Ltd acquired a new position in Synlogic during the fourth quarter worth $286,000. Institutional investors own 84.85% of the company’s stock.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Recommended Story: Momentum Investing
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.